Clinical Issues in Severe AsthmaConsensus and Controversies on the Road to Precision Medicine
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised,double-blind, placebo-controlled, phase 2b trial.
Brightling CE, et al. Lancet Respir Med. 2015;3(9):692-701.
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
Bleecker ER, et al. Lancet. 2016;388(10056):2115-2127.
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Castro M, et al. Lancet Respir Med. 2015;3(5):355-366.
A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
D’Amato G, et al. Ther Clin Risk Manag. 2007;3(4):613-619.
Darveaux J, Busse WW. J Allergy Clin Immunol Pract. 2015;3(2):152-161.
Denlinger LC, et al. Am J Respir Crit Care Med. 2017;195(3):302-313.
Haldar P, et al. Am J Respir Crit Care Med. 2008;178(3):218-224.
Gandhi NA, et al. Nat Rev Drug Discov. 2016;15(1):35-50
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM, et al. Lancet. 2016;388(10056):2128-2141.
Kim MA, et al. Curr Opin Allergy Clin Immunol. 2014;14(1):49-54.
Ortega HG, et al. N Engl J Med. 2014;371(13):1198-1207.
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG, et al. Lancet Respir Med. 2016;4(7):549-556
Passalacqua G, et al. Asthma Res Pract. 2015;1:6.
Porsbjerg C, Menzies-Gow, A. Respirology. 2017;22(4):651-661.
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Wenzel S, et al. Lancet. 2016;388(10039):31-44
Identifying Patients and Coordinating Multidisciplinary Care
Consensus and Controversies on the Road to Precision Medicine
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Improving Outcomes for Patients with COPD
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A New Era in Precision Medicine
Evolving Best Practices to Optimize Outcomes
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
Debates and Discussions About Personalizing Patient Management
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
From Guideline Recommendations to Daily Clinical Decision-Making
Improving Patient Outcomes Through Shared Clinical Decision Making
Interdisciplinary Management of Patients With Severe Asthma